



In 2021, Paxman began a process to help open access to Paxman Scalp Cooling to any US patient regardless of their insurance coverage or financial situation. Under this new system, any patient receiving solid tumors chemotherapy that is likely to cause alopecia will have a better chance of receiving scalp cooling coverage either through their insurance or another method.

CPT Codes effective November 21, 2021:

- 0662T: Scalp cooling mechanical; initial measurement and calibration of cap. This code is billed when the cap is fitted to the patient and may only be utilized one time per patient.
- 0663T: Placement of device, monitoring, and removal of device. This code is billed each time the patient receives scalp cooling during chemotherapy and is to be used in conjunction with chemotherapy administration codes 96409, 96411, 96413, 96415, 96416, and 96417.

ICD-10-CM Diagnosis Codes:

The Paxman Scalp Cooling System is indicated to reduce the likelihood of chemotherapy-induced alopecia (CIA) in cancer patients with solid tumors. Trials were done on patients who had solid tumors, such as ovarian, breast, colorectal and prostate cancers.

All diagnosis codes should correspond accurately to the patient's condition and at full discretion of the patient's physician.

Documentation:

- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) listing scalp cooling as a Category 2A recommendation
- ONS Guidelines™ for Cancer Treatment recommendation for scalp cooling
- Clinical information on scalp cooling is available at the Scalp Cooling Study Library
- Diagnosis codes on the claim form must match the patient medical record exactly
- The Paxman HUB performs benefits investigations for providers and will support provider offices with prior authorization and claim documentation, including suggested medical record criteria. The Paxman Hub (as well as our website) will provide sample letters of medical necessity and appeal, as well as suggested supporting materials such as the Paxman Scalp Cooling FDA Clearance and approved Indication for Use.

NCCN Guidelines:

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Breast Cancer V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 2, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.